Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Precision Therapy in Lung Cancer: FAQ on Biomarker Testing and Targeted Therapies

Listen to lung cancer experts Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer audience questions from a live CCO Webinar on biomarker testing and selecting targeted therapies for patients with advanced NSCLC.
Leora Horn, MD, MSc, FRCPC
Edward S. Kim, MD, FACP, FASCO
Released: August 10, 2020

In this episode, Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer questions focused on biomarker testing and selecting targeted therapy for patients with advanced non-small-cell lung cancer with topics including:

  • How to approach discordant results with liquid vs tissue biopsies
  • Repeating NGS testing at progression
  • Selecting urgent treatment when molecular results are not yet available
  • Point mutations in NTRK fusion–positive disease
  • Selecting second-line therapy for EGFR-positive disease with high PD-L1 expression after first-line TKI
  • Selecting first-line and second-line therapy for ROS1-positive disease
  • Standard of care for MET-altered disease
  • Selecting second-line therapy for RET fusion–positive disease after first-line TKI

Content based on an online CME program supported by an educational grant from Lilly.

Link to full program, including associated downloadable slidesets: https://www.clinicaloptions.com/oncology/programs/biomarkers-lung-cancer

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Related Content

Safety and response data from phase Ib TROPION-Lung02 study of Dato-DXd plus pembrolizumab with or without platinum chemotherapy in advanced NSCLC, presented at WCLC 2022 reported by Clinical Care Options (CCO)

Released: August 18, 2022

Results from the HUDSON umbrella trial of novel durvalumab combination regimens in patients with advanced NSCLC who failed previous immunotherapy treatment, presented at WCLC 2022 and reported by Clinical Care Options (CCO)

Released: August 18, 2022

Initial PFS and OS results from phase II NADIM II study of neoadjuvant nivolumab plus CT vs CT alone in patients with resectable stage IIIA-B NSCLC, presented at WCLC 2022 and reported by Clinical Care Options (CCO)

Released: August 18, 2022

Evaluation of YESS study adding personalized smoking cessation support to a lung cancer screening program, presented at WCLC 2022 and reported by Clinical Care Options (CCO)

Released: August 18, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings